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Background

Treatment and Outcome

• The TTN gene encodes Titin, the largest protein in the body and an essential
•
•
•

component of cardiac sarcomeres.
Mutations in the TTN gene are the most common known cause of dilated
cardiomyopathy and can lead to cardiac arrythmias.1
Studies have also suggested a link between TTN mutations and cancer
incidence and prognosis.2
Here we present a case of a 60-year-old male with a history of known
germline TTN mutation and atrial fibrillation who presented with
hyperthyroidism and was ultimately diagnosed with papillary thyroid
carcinoma.

Case Presentation

• A 60-year-old male presented with new onset atrial fibrillation and
•
•
•
•
•

• His hyperthyroidism was treated with methimazole, which he was able to stop

hyperthyroidism.
His past medical history was significant for germline TTN mutation and
recurrent ventricular tachycardia status post implantable cardiac defibrillator
placement.
He had been treated with amiodarone for two and a half years and had
stopped the medication eight months prior to presentation.
Laboratory workup was done (table 1) and an ultrasound of the thyroid gland
showed a multinodular goiter with subcentimeter cysts and a right lower lobe
nodule.
A follow-up thyroid ultrasound twelve months later showed a new 11 mm
nodule in the left lower lobe (Figure 1) and a stable 5 mm nodule in the right
lower lobe (Figure 2).
Fine needle aspiration of the left nodule was suspicious for follicular neoplasm
with suspicious Afirma Genome Sequence Classifier testing (corresponding to
~ 50% risk of malignancy).

•
•
•
Figure 1: Thyroid ultrasound showing
a mixed echogenicity solid nodule in
the left lower lobe, measuring 11 x 11 x
15 mm

Figure 2: Thyroid ultrasound showing a
solid nodule in the right lower lobe,
measuring 5 x 7 x 5 mm

• In this case, a 60-year-old male with a known germline TTN mutation
•

•

Initial Labs

Result (reference range)

Post Operative Labs

Result (reference range)

Thyroid Stimulating Hormone

<0.01 (0.25-4.50) uIU/mL

Thyroid Stimulating Hormone

1.19 (0.25-4.50) uIU/mL

Free Thyroxine (T4)

3.45 (0.80-1.80) ng/dL

Free Thyroxine (T4)

1.88 (0.80-1.80) ng/dL

Free Triiodothyronine (T3)

10.30 (2.30-3.80) pg/mL

Thyroglobulin

0.2 (2.8-40.9) ng/mL

Thyroid Stimulating Immunoglobulin

<89 (<140% baseline)

Thyroglobulin Antibody

11 (0.0-60) u/mL

Thyroid Peroxidase Antibody

<9 (0-31) u/mL

Table 1

Discussion

•

Figure 3: Representative histopathology showing a papillary microcarcinoma3

Table 2

after nine months.
Six months after discovery of the new left lower lobe thyroid nodule, the
patient underwent a total thyroidectomy and pathology showed a 1.5 mm
stage I papillary microcarcinoma in the right lower lobe (figures 3 and 4).
Post operative testing showed improvement and a low thyroglobulin level
(table 2).
His symptoms resolved and he is being treated with levothyroxine.

•

developed atrial fibrillation, hyperthyroidism, and papillary thyroid carcinoma.
Mutations in the TTN gene may be associated with early onset atrial
fibrillation. In one study, a loss of function mutation in a TTN gene was
associated with increased odds of atrial fibrillation (OR 1.76 (95% CI 1.042.97).4
The patient’s hyperthyroidism was presumed to be due to his previous
amiodarone use. There are two forms of amiodarone induced hyperthyroidism
(AIT). Type I AIT is more likely in the presence of underlying thyroid nodules or
latent Graves disease, and typically occurs early after amiodarone is started,
and is due to increased thyroid hormone synthesis. Type II AIT is a destructive
thyroiditis and is more likely in patients without underlying thyroid disease.
When amiodarone induced hyperthyroidism (AIT) starts after amiodarone
discontinuation, it is more likely to be due to type II AIT.5 Despite, the timing of
his hyperthyroidism, he was treated with methimazole for type I AIT due to his
multinodular goiter and responded well.
Interestingly, this patient was later discovered to have papillary thyroid
microcarcinoma. A recent study by Han et al found that TTN is one of the top
five mutated genes in thyroid cancer, together with BRAF, NRAS, HRAS, and
thyroglobulin.2 They also found an association between TTN mutations in
thyroid cancer and worse prognosis. However, they did not distinguish
between germline vs. tumor specific TTN mutations.
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